This research explores how pneumococcus precisely builds diverse glycans without templates, engineering capsule pathways to produce defined glycans, reveal antimicrobial targets, and develop programmable platforms for next-generation vaccines and therapeutics.

Professor Alonso’s pioneering dengue and HFMD research advanced understanding of viral severity and immune evasion, while her vaccine platform shows promise for durable single-dose protection against major infectious diseases.

Some ideas begin with evidence. Others begin with possibility, long before evidence catches up. This journey started with an N=1: a single question, a single patient, a single story, and grew into something tested, challenged and refined into CURATE.AI, before making a meaningful difference to the people it touched.

Latest research on polygenic scores explores their construction, cataloging, and clinical use, integrating multi-omics data to improve disease risk prediction and identify molecular mediators in coronary artery disease and diabetes.

Professor Paul MacAry’s pioneering antibody biology research has reshaped understanding of immunity in infection, cancer, ageing, and inflammation, advancing therapeutics, biomarkers, and immune profiling through globally recognised achievements.

Associate Professor Clemmensen investigates brain regulation of metabolism, translating discoveries into therapies for cardiometabolic and neurodegenerative diseases, including peptide–drug conjugates for weight loss through Ousia Pharma.